Press Releases

News Brief

Samsung Biologics to showcase strengthened development capabilities and business expansion updates at CPHI 2023

Samsung Biologics to showcase strengthened development capabilities and business expansion updates at CPHI 2023

Samsung Biologics will be attending CPHI Barcelona between October 24-26 as the event’s official registration and welcome partner.

 

As a trusted CDMO partner, the company will demonstrate how its strengthened chemical, manufacturing, and control (CMC) solution packages and new proprietary development platforms – S-KiH and S-GlynTM – can accelerate clients’ drug development journey and maximize the potential of their molecule.

 

Samsung Biologics will also share its latest expansion plans regarding the construction of its new Plant 5, the first facility of its second Bio Campus  at their Songdo headquarters. When operational by April 2025, the company will continue to hold the world’s largest manufacturing capacity with 784,000 liters.

 

Samsung Biologics is also adding an antibody-drug conjugate (ADC) facility, which is expected to be cGMP-ready within 2024.

 

As part of its ongoing sustainability efforts, the company has built an eco-friendly booth with reusable materials and reduced waste by incorporating QR technology within the booth.

 

Meet the Samsung Biologics team at Booth #3K40 or schedule a meeting here

Samsung Biologics to showcase strengthened development capabilities and business expansion updates at CPHI 2023

Samsung Biologics will be attending CPHI Barcelona between October 24-26 as the event’s official registration and welcome partner.

 

As a trusted CDMO partner, the company will demonstrate how its strengthened chemical, manufacturing, and control (CMC) solution packages and new proprietary development platforms – S-KiH and S-GlynTM – can accelerate clients’ drug development journey and maximize the potential of their molecule.

 

Samsung Biologics will also share its latest expansion plans regarding the construction of its new Plant 5, the first facility of its second Bio Campus  at their Songdo headquarters. When operational by April 2025, the company will continue to hold the world’s largest manufacturing capacity with 784,000 liters.

 

Samsung Biologics is also adding an antibody-drug conjugate (ADC) facility, which is expected to be cGMP-ready within 2024.

 

As part of its ongoing sustainability efforts, the company has built an eco-friendly booth with reusable materials and reduced waste by incorporating QR technology within the booth.

 

Meet the Samsung Biologics team at Booth #3K40 or schedule a meeting  here

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION